Trastuzumab (T) plus vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer.

被引：0
|
作者：
Glogowska, I [1 ]
Sienkiewicz-Kozlowska, R [1 ]
Bauer-Kosinska, B [1 ]
Jaczewska, S [1 ]
Pienkowski, T [1 ]
机构：
[1] Mem Marie Sklodowska Curie Canc Ctr, Warsaw, Poland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3165
引用
收藏
页码：235S / 235S
页数：1
相关论文
共 50 条
  • [31] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    [J]. Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [33] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [34] Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Giuliani, Rosa
    Durbecq, Virginie
    Di Leo, Angelo
    Paesmans, Marianne
    Larsimont, Denis
    Leroy, Jean-Yves
    Borms, Marleen
    Vindeuoghel, Anita
    Jerusalem, Guy
    D'Hondt, Veronique
    Dirix, Luc
    Canon, Jean-Luc
    Richard, Vincent
    Cocquyt, Veronique
    Majois, Francoise
    Reginster, Michel
    Demol, Jan
    Kains, Jean-Pierre
    Delree, Paul
    Keppens, Carine
    Sotiriou, Christos
    Piccart, Martine J.
    Cardoso, Fatima
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 725 - 735
  • [35] Trastuzumab and oral vinorelbine (±endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer.
    Torrisi, R.
    Magni, E.
    Dellapasqua, S.
    D'Alessandro, C.
    Veronesi, P.
    Luini, A.
    Minchella, I
    Ghisini, R.
    Nole, F.
    Viale, G.
    Goldhirsch, A.
    Colleoni, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [36] Incidence of brain metastasis (BM) in HER-2 overexpressing metastatic breast cancer (MBC) responsive to trastuzumab
    Stemmler, J
    Kahlert, S
    Siekiera, W
    Heinrich, B
    Untch, M
    Heinemann, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S130 - S130
  • [37] Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1
    Harbeck, Nadia
    Huang, Chiun-Sheng
    Hurvitz, Sara
    Yeh, Dah-Cherng
    Shao, Zhimin
    Im, Seock-Ah
    Jung, Kyung Hae
    Shen, Kunwei
    Ro, Jungsil
    Jassem, Jacek
    Zhang, Qingyuan
    Im, Young-Hyuck
    Wojtukiewicz, Marek
    Sun, Qiang
    Chen, Shin-Cheh
    Goeldner, Rainer-Georg
    Lahogue, Annick
    Uttenreuther-Fischer, Martina
    Xu, Binghe
    Piccart-Gebhart, Martine
    [J]. CANCER RESEARCH, 2015, 75
  • [38] Trastuzumab and Vinorelbine combination in the treatment of metastatic breast cancer
    Bayo, J. L.
    Mayordomo, J. I.
    Rovira, P. Sanchez
    Gonzalez, E.
    Bueno, J. M. Garcia
    Ramos, M.
    Crespo, C.
    Illarramendi, J.
    Valerdi, J.
    Palomo, A. Garcia
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 130 - 130
  • [39] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
  • [40] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    [J]. CANCER RESEARCH, 2013, 73
12345